ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

Rhea-AI Summary

ProQR (Nasdaq: PRQR) will host a virtual Investor and Analyst Event on April 8, 2026 from 10:00 am ET covering its Axiomer™ RNA editing pipeline.

The company will highlight programs beyond AX-0810, announce new programs with upcoming clinical readouts, and unveil AX-0810's primary indication ahead of target engagement data expected in H1 2026.

News Market Reaction – PRQR

+6.04%

1 alert

+6.04% News Effect

+$9M Valuation Impact

$166M Market Cap

0.4x Rel. Volume

On the day this news was published, PRQR gained 6.04%, reflecting a notable positive market reaction. This price movement added approximately $9M to the company's valuation, bringing the market cap to $166M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Event date: April 8, 2026 Event start time: 10:00 am ET Event end time: 11:30 am ET +1 more

4 metrics

Event date April 8, 2026 Virtual Investor and Analyst Event

Event start time 10:00 am ET Start of virtual event

Event end time 11:30 am ET Scheduled end of virtual event

AX-0810 target data timing First half of 2026 Anticipated target engagement data for AX-0810

Market Reality Check

Price: $1.58 Vol: Volume 258,271 vs 20-day ...

normal vol

$1.58 Last Close

Volume Volume 258,271 vs 20-day average 303,130, indicating slightly below-typical activity ahead of the event announcement. normal

Technical Shares at $1.49 are trading below the 200-day MA of $2.06 and about 51.94% below the 52-week high of $3.10.

Peers on Argus

PRQR was down 3.87% with several RNA/biotech peers also lower: EDIT -4.06%, SLN ...

1 Up

PRQR was down 3.87% with several RNA/biotech peers also lower: EDIT -4.06%, SLN -7.96%, THRD -0.55%, VOR -2.10%, while ACIU was flat. This points to a broader weak tone in related biotech names rather than a purely idiosyncratic move.

Historical Context

5 past events · Latest: Mar 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Year-end results	Neutral	-5.0%	Reported 2025 financials, cash runway into mid-2027, and pipeline updates.
Mar 03	Conference presentation	Positive	+13.3%	Announced webcast of Citizens Life Sciences Conference presentation with management.
Feb 09	Board changes	Neutral	-2.0%	Planned board rotations and search for new directors at 2026 AGM.
Jan 08	Clinical data update	Positive	-2.8%	Encouraging AX-0810 Phase 1 safety/PK data and new development candidates.
Dec 01	Conference participation	Neutral	-9.4%	Participation in Evercore Healthcare Conference to discuss Axiomer platform.

Pattern Detected

Recent news often saw mixed to negative price reactions, including a decline after encouraging AX-0810 Phase 1 data.

Recent Company History

Over the last few months, ProQR highlighted progress on its Axiomer RNA editing platform and lead candidate AX-0810. On Jan 8, 2026, it reported encouraging Phase 1 safety and PK data for AX-0810 and selected development candidates AX-2402 and AX-2911, yet shares fell 2.78%. Year-end 2025 results on Mar 12, 2026 showed cash of €92.4M and runway into mid-2027, but the stock declined 4.97%. Conference participation and board changes generated mixed reactions, framing today’s pipeline-focused event announcement within an already active communications pattern.

Market Pulse Summary

The stock moved +6.0% in the session following this news. A strong positive reaction aligns with gro...

Analysis

The stock moved +6.0% in the session following this news. A strong positive reaction aligns with growing investor focus on ProQR’s Axiomer RNA editing pipeline. The event on April 8, 2026 promised new programs, clinical data timelines, and the primary indication for AX-0810, following earlier Phase 1 safety and PK data. Past announcements sometimes saw muted or negative moves, so any outsized gain could reflect shifting sentiment rather than fundamentals alone, and might be sensitive to later AX-0810 target engagement results.

Key Terms

rna therapies, axiomer, rna editing, target engagement

4 terms

rna therapies medical

"a company dedicated to changing lives through transformative RNA therapies based on its"

RNA therapies are medicines that use molecules similar to the body’s genetic messages to change how cells behave — for example by telling cells to make a missing protein, blocking a harmful one, or altering gene expression. Think of them as software updates for cells that can target diseases at their instruction level; they matter to investors because they promise highly specific treatments with large market potential but also carry clinical, manufacturing and regulatory risks that can cause big swings in value.

axiomer medical

"through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology"

Axiomer is a platform technology that directs the cell’s natural RNA-editing machinery to change single letters in messenger RNA, temporarily altering how a protein is made without changing the underlying DNA. For investors, it matters because such a technology can turn into multiple drug candidates across diseases like a software toolkit: success boosts future product potential and licensing value, while failures affect projected pipeline and partner income.

rna editing medical

"based on its proprietary Axiomer™ RNA editing technology platform, today announced that it"

RNA editing is a natural or engineered process that changes the molecular message copied from a gene before it is used to make a protein, like tweaking a recipe after it’s written to alter the final dish. For investors, RNA editing matters because it enables new kinds of medicines and diagnostics — promising bigger returns but also carrying technical, safety and regulatory risks that can strongly affect a biotech company’s value.

target engagement medical

"Ahead of the anticipated target engagement data for AX-0810 in the first half of 2026"

Target engagement measures how effectively a medicine interacts with the specific biological molecule or pathway it is designed to affect—think of it as how well a key fits and turns a particular lock inside the body. Investors watch target engagement because clear, measurable interaction at safe doses increases the likelihood the drug will produce the intended effect, helps set dosing and trial decisions, and reduces the risk that development will fail later.

AI-generated analysis. Not financial advice.

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will host a virtual Investor and Analyst Event highlighting its pipeline entitled:

“Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”

Ahead of the anticipated target engagement data for AX-0810 in the first half of 2026, the Company will showcase ProQR’s broader RNA editing pipeline at this event, announce new programs that will have clinical data readouts in the runway, and unveil the primary indication for AX-0810.

Event Details and Registration

• Title: Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810
• Date & Time: April 8, 2026 beginning at 10:00 am ET until approximately 11:30 am ET
• Virtual format: Webcast presentations and Q&A with covering analysts and Management
• Registration: https://lifescievents.com/event/g09gufqylu/

About Axiomer^™

ProQR is pioneering a next-generation RNA base editing technology called Axiomer^™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer^™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer^™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer^™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “continue,” "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our business, technology, strategy, preclinical and clinical model data; our initial pipeline targets and the upcoming strategic priorities and milestones related thereto; our new pipeline targets, the continued advancement of our lead development pipeline programs, including approved, ongoing and planned clinical trials; expectations regarding the ongoing Phase 1 clinical study of AX-0810 in NTCP for cholestatic diseases; expectations regarding the safety and therapeutic benefits of AX-0810, including the planned dosing levels and their efficacy; the anticipated timing of initial Phase 1 clinical data for our lead program, AX-0810, in H1, 2026, and clinical updates across multiple programs in 2026; the continued development and advancement of our Axiomer^™ platform; the therapeutic potential of our Axiomer RNA editing oligonucleotides and product candidates; the timing, progress and results of our preclinical studies and other development activities, including the release of data related thereto; our patent estate, including our anticipated strength and our continued investment in it; and the potential of our technologies and product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions[, U.S. government shutdown] and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical events and conflicts, high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com

FAQ

When will ProQR (PRQR) host the virtual investor and analyst event on Axiomer RNA editing?

ProQR will host the virtual event on April 8, 2026 starting at 10:00 am ET. According to the company, the webcast runs until approximately 11:30 am ET and includes presentations and live Q&A with management and covering analysts.

What will ProQR (PRQR) present about AX-0810 at the April 8, 2026 event?

ProQR will unveil the primary indication for AX-0810 at the event. According to the company, this is timed ahead of anticipated AX-0810 target engagement data expected in the first half of 2026.

Will ProQR (PRQR) announce new programs at the April 8, 2026 investor event?

Yes. ProQR will announce new programs with upcoming clinical data readouts. According to the company, the event will showcase the broader RNA editing pipeline beyond AX-0810 and timing of near‑term clinical readouts.

How can investors register for ProQR's (PRQR) April 8, 2026 webcast?

Investors can register via the event registration link provided by the company. According to the company, the virtual format includes webcast presentations and a Q&A session; registration is required to access the live webcast.

Why is ProQR (PRQR) holding the April 8, 2026 event before AX-0810 target engagement data?

ProQR aims to outline its broader RNA editing strategy and near‑term clinical plans ahead of data. According to the company, the event will contextualize AX-0810 within the pipeline and preview upcoming clinical milestones in H1 2026.